Overexpression of p21(WAF1-CIP1) and MDM2 characterizes serous borderline ovarian tumors

Human Pathology

Volumn 31, Issue 6, 2000, Pages 698-704

  Palazzo, Juan P ^a   Monzon, Federico ^a   Burke, Melissa ^a   Hyslop, Terry ^a   Dunton, Charles ^a   Barusevicius, Alan ^a   Capuzzi, David ^a   Kovatich, Albert J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Immunohistochemistry; Ki 67; MDM2; Ovarian epithelial tumors; p21(WAF1 CIP1); p53

Indexed keywords

PROTEIN P21; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; KI 67 ANTIGEN; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CELL CYCLE; DISEASE ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY TUMOR; PATHOGENESIS; PROTEIN EXPRESSION; TRANSACTIVATION; TUMOR GROWTH; BIOSYNTHESIS; CHEMISTRY; CYSTADENOMA; FEMALE; GENE EXPRESSION; METABOLISM;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTADENOMA, SEROUS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; HUMANS; KI-67 ANTIGEN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033623884     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2000.7641     Document Type: Article

References (40)

1. Sherr C.J. Cancer cell cycles Science 274 1996 1672 1677
2. MacLachlan T.K. Sang N. Giordano A. Cyclins, cyclin-dependent kinases an CDK inhibitors: Implications in cell cycle control and cancer Critical Reviews in Eukaryotic Gene Expression 5 1995 127 156
3. Hollstein M. Sidransky D. Vogelstein B. p53 mutations in human cancers Science 253 1991 49 53
4. Hartwell L.H. Kasten M.B. Cell cycle control and cancer Science 266 1994 1821 1828
5. Sherr C.J. G1 phase progression: Cycling on cue Cell 79 1994 551 555
6. Hunter T. Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age Cell 79 1994 573 582
7. El-Derry W.S. Tokino T. Velculescu D.B, WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
8. Xiong Y. Hannon G.J. Zhang H. p21 is a universal inhibitor of cyclin kinases Nature (London) 366 1993 701 704
9. El-Derry W.S. Harper J.W. O'Connor P.M. WAF1/CIPI is induced in p53-mediated G1 arrest and apoptosis Cancer Res 54 1994 1169 1174
10. Li Y. Jenkins C.W. Nichols M.A. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21 Oncogene 9 1994 2261 2268
11. WAF1/CIP1 in normal, hyperplastic and neoplastic uterine tissues Hum PATROL 27 1997 60 66
12. Sheikh M.S. Li X.S. Chen J.C. Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways Oncogene 9 1994 3407 3415
13. WAF1/CIP1 expression in normal human tissues Am J Pathol 148 1996 825 835
14. WAF1/CIP1 and bcl-2 in radioresistant colorectal carcinoma Hum PATROL 28 1997 1189 1195
15. Shiohara M. El-Deity W.S. Wada M. Absence of WAFT mutations in a variety of human malignancies Blood 84 1994 3781 3784
16. Freedman D.A. Levine A.J. Regulation of the p53 rotein by the MDM2 oncoprotein: Thirty-Eight G.H.A. Clowes Memorial Award Lecture Cancer Res 59 1999 1 7
17. Momand J. Jung D. Wilczynski S. The MDM2 gene amplification database Nucleic Acid Res 26 1998 3453 3459
18. Brown D.R. Thomas C.A. Deb S.P. The human oncoprotein MDM2 arrests the cell cycle: Elimination of its cell-cycle-inhibitory function induces tumorigencsis EMBO J 17 1998 2513 2525
19. Link C.J. Reed E. Sarosy G. Kohn E.C. Borderline ovarian tumors Am J Med 101 1996 217 225
20. Link C.J. Kohn E. Reed E. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: Epidemiologic, pathologic, and molecular aspects Gynecol Oncol 60 1996 347 354
21. Kurman R.J. Trimble C.L. The behavior of serous tumors of low malignant potential: Are they ever malignant? Int J Gynecol Pathol 12 1993 120 127
22. Serov S.F. Scully R.E. Sobin L.H. Histological typing of ovarian tumours 1973 World Health Organization Geneva, Switzerland
23. Hollander M. Wolfe D.A. Nonparametric Statistical Methods 1973 John Wiley & Sons New York, NY
24. Siegel S. Castellan N.J. Nonparametric Statistics for the Behavioral Sciences ed 2 1988 McGraw-Hill New York, NY
25. Garzeti G.G. Ciavattini A. Goteri G. Ki67 antigen Immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: Index of proliferative activity with prognostic significance Gynecol Oncol 56 1995 169 174
26. Gallion H.H. Pieretti M. DePriest P.D. The molecular basis of ovarian cancer Cancer 76 1995 1992 1997
27. Kupryjanczyk Jolanta Bell D.A. Yandell D.W. p53 expression in ovarian borderline tumors and stage I carcinomas Am J Clin Pathol 102 1994 671 676
28. Kupryjanczyk J. Bell D.A. Dimeo D. p53 gene analysis of ovarian borderline tumors and stage I carcinomas Hum PAThOL 1995 387 392
29. Klemi P.J. Takahashi S. Joensuu H. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors Int J Gynecol Pathol 13 1994 228 233
30. Kijokawa T. Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression Int J Gynecol Pathol 13 1994 311 318
31. Berchuck A. Kohler M.F. Hopkins M.P. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors Gynecol Oncol 52 1994 232 236
32. Marcelli A.R. Demopoulos R.I. Goswami S. Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors Int J Gynecol Pathol 15 1996 39 44
33. Eltabbakh G.H. Belinson J.L. Kennedy A.W. p53 and HER 2/neu overexpression in ovarian borderline tumors Gynecol Oncol 65 1997 218 224
34. Lukas J. Groshen S. Saffari B. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium Am J Pathol 150 1997 167 175
35. Shimizu M. Nikaido T. Toki T. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas Cancer 85 1999 669 677
36. WAF1/CIP1 in ovarian carcinomas: Correlation with p53 and Ki-67 immunohistochemistry Int J Gynecol Pathol 16 1997 149 155
37. WAF1/CIP1 predictssurvival and good response to Platinin-based chemotherapy Hum PATROL 30 1999 640 647
38. Skomedal H. Kristensen G.B. Abeler V.M. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas J Pathol 181 1997 158 165
39. Weber J.D. Taylor L.J. Roussel M.F. Nucleolar Arf sequesters MDM2 and activates p53 Nature 1 1999 20 25
40. Meltzer P.S. MDM2 and p53: A question of balance J Natl Cancer Inst 86 1994 1265 1266